Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling

Electronic Journal of Biotechnology

Volumn 15, Issue 5, 2012, Pages 5-

  Courtois, Anthony ^a,b   Gac Breton, Stéphanie ^a   Berthou, Christian ^b   Guézennec, Jean ^a   Bordron, Anne ^b   Boisset, Claire ^a,c  

^a TECHNOPÔLE BREST IROISE   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c Morlaix Chamber of Commerce and Industry ^*  (France)

Author keywords

Complement system; Gal (1 3)gal epitope; Immunogenic oligosaccharide; Immunotherapy; Non hodgkin lymphoma; Xenoantigen

Indexed keywords

BIOCHEMICAL METHODS; BIOCONJUGATES; CELL LINES; CELL TARGETING; COMPLEMENT SYSTEMS; COMPLEMENT-DEPENDENT CYTOTOXICITIES; FAB FRAGMENTS; IMMUNE RESPONSE; IMMUNOTHERAPY; IN-VITRO ASSAYS; MONOCLONAL ANTIBODIES (MABS); NON-HODGKIN LYMPHOMA; RECOGNITION CAPACITY; THERAPEUTIC ANTIBODIES; XENOANTIGEN;

ANTIGENS; BIOMOLECULES; CELL CULTURE; CHEMICAL ACTIVATION; CHEMOTHERAPY; CYTOTOXICITY; MONOCLONAL ANTIBODIES; ONCOLOGY;

OLIGOSACCHARIDES;

CD20 ANTIGEN; EPITOPE; GALACTOSE ALPHA(1-3)GALACTOSE BETA(1-4)N ACETYLGLUCOSAMINE TRISACCHARIDE; GALACTOSE ALPHA(1-3)GALACTOSE BETA(1-4)N ACETYLGLUCOSAMINE TRISACCHARIDE RITUXIMAB FAB FRAGMENT CONJUGATE; GLYCAN; OLIGOSACCHARIDE; RITUXIMAB; RITUXIMAB FAB FRAGMENT; TRISACCHARIDE; UNCLASSIFIED DRUG; ALPHA GALACTOSIDASE; BETA GALACTOSIDASE; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELL ASSAY; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; COVALENT BOND; DAUDI CELL; DRUG BINDING; DRUG CONJUGATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MOLECULAR RECOGNITION; TUMOR GROWTH; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; COMPLEMENT INHIBITION; CONJUGATION;

EID: 84866609382     PISSN: None     EISSN: 07173458     Source Type: Journal    
DOI: 10.2225/vol15-issue5-fulltext-3     Document Type: Article

References (35)

1. Abdel-Motal, U.M.; WIGGLESWORTH, K. and GALILI, U. (2009). Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunology, Immunotherapy, vol. 58, no. 10, p. 1545-1556. [CrossRef]
2. ALDOSS, I.T.; WEISENBURGER, D.D.; FU, K.; CHAN, W.C.; VOSE, J.M.; BIERMAN, P.J.; BOCIEK, R.G. and ARMITAGE, J.O. (2008). Adult Burkitt lymphoma: Advances in diagnosis and treatment. Oncology (Williston Park), vol. 22, no. 13, p. 1508-1517.
3. ANNUNZIATO, M.E.; PATEL, U.S.; RANADE, M. and PALUMBO, P.S. (1993). P-Maleimidophenyl isocyanate: A novel heterobifunctional linker for hydroxyl to thiol coupling. Bioconjugate Chemistry, vol. 4, no. 3, p. 212-218. [CrossRef]
4. BEUM, P.V.; LINDORFER, M.A.; BEURSKENS, F.; STUKENBERG, P.T.; LOKHORST, H.M.; PAWLUCZKOWYCZ, A.W.; PARREN, P.W.; van de Winkel, J.G. and TAYLOR, R.P. (2008). Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. The Journal of Immunology, vol. 181, no. 1, p. 822-832.
5. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, vol. 71, no. 1-2, p. 248-254. [CrossRef]
6. BRINKLEY, M. (1992). A brief survey of methods for preparing protein conjugates with dyes, haptens, and crosslinking reagents. Bioconjugate Chemistry, vol. 3, no. 1, p. 2-13. [CrossRef]
7. CARDARELLI, P.M.; QUINN, M.; BUCKMAN, D.; FANG, Y.; COLCHER, D.; KING, D.J.; BEBBINGTON, C. and YARRANTON, G. (2002). Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunology, Immunotherapy, vol. 51, no. 1, p. 15-24. [CrossRef]
8. CHOLUJOVA, D.; JAKUBIKOVA, J. and SEDLAK, J. (2009). BioBran-augmented maturation of human monocyte derived dendritic cells. Neoplasma, vol. 56, no. 2, p. 89-95. [CrossRef]
9. COURTOIS, A.; Simon-Colin, C.; BOISSET, C.; BERTHOU, C.; DESLANDES, E.; GUÉZENNEC, J. and BORDRON, A. (2008). Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway. Marine Drugs, vol. 6, no. 3, p. 407-417. [CrossRef]
10. EDWARDS, J.C.; LEANDRO, M.J. and CAMBRIDGE, G. (2002). B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochemical Society Transactions, vol. 30, no. 4, p. 824-828. [CrossRef]
11. EISENBERG, R. (2003). SLE - Rituximab in lupus. Arthritis Research & Therapy, vol. 5, no. 4, p. 157-159. [CrossRef]
12. ELLMAN, G.L. (1959). Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics, vol. 82, no. 1, p. 70-77. [CrossRef]
13. GALILI, U.; SHOHET, S.B.; KOBRIN, E.; STULTS, C.L. and MACHER, B.A. (1988). Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. The Journal of Biological Chemistry, vol. 263, no. 33, p. 17755-17762.
14. GALILI, U. and LATEMPLE, D.C. (1997). Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunology Today, vol. 18, no. 6, p. 281-285. [CrossRef]
15. GALILI, U. (2001). The α-gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation. Biochimie, vol. 83, no. 7, p. 557-563. [CrossRef]
16. GALILI, U.; CHEN, Z.C. and DEGEEST, K. (2003). Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. Gynecologic Oncology, vol. 90, no. 1, p. 100-108. [CrossRef]
17. GOTTARDO, N.G.; BAKER, D.L. and WILLIS, F.R. (2003). Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab. Pediatric Hematology-Oncology, vol. 20, no. 7, p. 557-561. [CrossRef]
18. JUHL, H.; PETRELLA, E.C.; CHEUNG, N.K.; BREDEHORST, R. and VOGEL, C.W. (1990). Complement killing of human neuroblastoma cells: A cytotoxic monoclonal antibody and its F(ab)'2-cobra venom factor conjugate are equally cytotoxic. Molecular Immunology, vol. 27, no. 10, p. 957-964. [CrossRef]
19. KAZATCHKINE, M.; HAUPTMANN, G. and NYDEGGER, U. (1985). Dosages hémolytiques des composants du Complément. In: Techniques du Complément, Techniques en Immunologie. INSERM, Paris: Société Française d'Immunologie. p. 15-44.
20. LATEMPLE, D.C.; HENION, T.R.; ANARAKI, F. and GALILI, U. (1996). Synthesis of α-galactosyl epitopes by recombinant α1,3galactosyltransferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Research, vol. 56, no. 13, no. 3069-3074.
21. MANCHES, O.; LUI, G.; CHAPEROT, L.; GRESSIN, R.; MOLENS, J.P.; JACOB, M.C.; SOTTO, J.J.; LEROUX, D.; BENSA, J.C. and PLUMAS, J. (2003). In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood, vol. 101, no. 3, p. 949-954. [CrossRef]
22. MCMORROW, I.M.; COMRACK, C.A.; SACHS, D.H. and DERSIMONIAN, H. (1997). Heterogeneity of human antipig natural antibodies cross-reactive with the gal([alpha]1,3)galactose epitope 1. Transplantation, vol. 64, no. 3, p. 501-510.
23. OUCHTERLONY, Ö. (1958). Diffusion-in-gel methods for immunological analysis. Progress in Allergy, vol. 5, p. 1-78. [CrossRef]
24. REITER, Y. and FISHELSON, Z. (1989). Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. The Journal of Immunology, vol. 142, no. 8, p. 2771-2777.
25. SANDRIN, M.S.; VAUGHAN, H.A.; DABKOWSKI, P.L. and MCKENZIE, I.F. (1993). Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proceedings of the National Academy Sciences of the United States of America, vol. 90, no. 23, p. 11391-11395.
26. SEHN, L.H. (2008). Management of Burkitt lymphoma: A continuing challenge. Oncology (Williston Park), vol. 22, no. 13, p. 1519-1522-3.
27. SHAN, D.; LEDBETTER, J.A. and PRESS, O.W. (2000). Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology, Immunotherapy, vol. 48, no. 12, p. 673-683. [CrossRef]
28. THOMPSON, S. (2004). Small-molecule-protein conjugation procedures. Molecular Diagnosis of Infectious Diseases, Methods in Molecular Medicine, vol. 94, p. 255-265. [CrossRef]
29. VAN MEERTEN, T.; VAN RIJN, R.S.; HOL, S.; HAGENBEEK, A. and EBELING, S.B. (2006). Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical Cancer Research, vol. 12, no. 13, p. 4027-4035. [CrossRef]
30. WALPEN, A.J.; MOHACSI, P.; FREY, C.; ROOS, A.; DAHA, M.R. and RIEBEN, R. (2002). Activation of complement pathways in xenotransplantation: An in vitro study. Transplant Immunology, vol. 9, no. 2-4, p. 271-280. [CrossRef]
31. WANG, Y.; FEI, D.; VANDERLAAN, M. and SONG, A. (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, vol. 7, no. 4, p. 335-345. [CrossRef]
32. WANG, S.Y.; RACILA, E.; TAYLOR, R.P. and WEINER, G.J. (2008). NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood, vol. 111, no. 3, p. 1456-1463. [CrossRef]
33. XIAO, S.J.; BRUNNER, S. and WIELAND, M. (2004). Reactions of surface amines with heterobifunctional crosslinkers bearing both succinimidyl ester and maleimide for grafting biomolecules. The Journal of Physical Chemistry B, vol. 108, no. 42, p. 16508-16517. [CrossRef]
34. ZECCA, M.; NOBILI, B.; RAMENGHI, U.; PERROTTA, S.; AMENDOLA, G.; ROSITO, P.; JANKOVIC, M.; PIERANI, P.; DE STEFANO, P.; BONORA, M.R. and LOCATELLI, F. (2003). Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood, vol. 101, no. 10, p. 3857-3861. [CrossRef]
35. ZHENG, X.; PALLERA, A.M.; GOODNOUGH, L.T.; SADLER, J.E. and BLINDER, M.A. (2003). Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Annals of Internal Medicine, vol. 138, no. 2, p. 105-108.